CHANNEL THERAPEUTICS CORP (CHRO) Stock Price, Quote, News and Overview
NYSEARCA:CHRO - NYSE Arca - US1711261057 - Common Stock - Currency: USD
CHRO Quote, Performance and Key Statistics
1.68
+0.05 (+3.07%)
The current stock price of CHRO is 1.68 USD. In the past month the price decreased by -39.78%. In the past year, price decreased by -61.2%.
CHRO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CHRO
Company Profile
Chromocell Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. The company is headquartered in Freehold, New Jersey and currently employs 4 full-time employees. The company went IPO on 2024-02-16. Its clinical focus is to selectively target the sodium ion-channel, NaV1.7, which has been genetically validated as a pain receptor in human physiology. The company operates three programs developing pain treatment therapeutics: Neuropathic Pain, Eye Pain, and Depot. The company is engaged in developing, CC8464, to address certain types of neuropathic pain. The chemical characteristics of CC8464 restrict its entry into the CNS and limit its effect to the NaV1.7 channels in the peripheral nervous system. Based on a novel formulation of CC8464, its Eye Pain program, titled CT2000, is for the potential treatment of both acute and chronic eye pain. Based on several novel formulations of CC8464, its program, titled CT3000, is for the potential treatment of postoperative pain with the use of nerve blocks.
Company Info
CHANNEL THERAPEUTICS CORP
4400 Route 9 South, Suite 1000
Freehold NEW JERSEY US
Employees: 4
Company Website: https://ir.chromocell.com/
Phone: 18772658266
CHANNEL THERAPEUTICS CORP / CHRO FAQ
What is the stock price of CHANNEL THERAPEUTICS CORP today?
The current stock price of CHRO is 1.68 USD. The price increased by 3.07% in the last trading session.
What is the ticker symbol for CHANNEL THERAPEUTICS CORP stock?
The exchange symbol of CHANNEL THERAPEUTICS CORP is CHRO and it is listed on the NYSE Arca exchange.
On which exchange is CHRO stock listed?
CHRO stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for CHANNEL THERAPEUTICS CORP stock?
7 analysts have analysed CHRO and the average price target is 8.67 USD. This implies a price increase of 416.07% is expected in the next year compared to the current price of 1.68. Check the CHANNEL THERAPEUTICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CHANNEL THERAPEUTICS CORP worth?
CHANNEL THERAPEUTICS CORP (CHRO) has a market capitalization of 10.13M USD. This makes CHRO a Nano Cap stock.
How many employees does CHANNEL THERAPEUTICS CORP have?
CHANNEL THERAPEUTICS CORP (CHRO) currently has 4 employees.
What are the support and resistance levels for CHANNEL THERAPEUTICS CORP (CHRO) stock?
CHANNEL THERAPEUTICS CORP (CHRO) has a support level at 1.62 and a resistance level at 1.88. Check the full technical report for a detailed analysis of CHRO support and resistance levels.
Should I buy CHANNEL THERAPEUTICS CORP (CHRO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CHRO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CHRO, evaluating the profitability, health, valuation and growth aspects
- CHANNEL THERAPEUTICS CORP (CHRO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CHANNEL THERAPEUTICS CORP (CHRO) Sales and EPS estimates to see what analysts future expectations are.
- CHANNEL THERAPEUTICS CORP (CHRO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CHANNEL THERAPEUTICS CORP (CHRO) Insider and Institutional Ownership to learn about the owners and their transactions.
- CHANNEL THERAPEUTICS CORP (CHRO) Stock Chart to make your own analysis
- CHANNEL THERAPEUTICS CORP (CHRO) Latest news and press-releases to stay up to date.
Does CHANNEL THERAPEUTICS CORP (CHRO) stock pay dividends?
CHRO does not pay a dividend.
What is the Price/Earnings (PE) ratio of CHANNEL THERAPEUTICS CORP (CHRO)?
CHANNEL THERAPEUTICS CORP (CHRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.67).
What is the Short Interest ratio of CHANNEL THERAPEUTICS CORP (CHRO) stock?
The outstanding short interest for CHANNEL THERAPEUTICS CORP (CHRO) is 12.89% of its float. Check the ownership tab for more information on the CHRO short interest.
CHRO Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CHRO. When comparing the yearly performance of all stocks, CHRO is one of the better performing stocks in the market, outperforming 93.84% of all stocks.
CHRO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CHRO. The financial health of CHRO is average, but there are quite some concerns on its profitability.
CHRO Financial Highlights
Over the last trailing twelve months CHRO reported a non-GAAP Earnings per Share(EPS) of -1.67. The EPS decreased by -203.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -222.66% | ||
| ROE | -794.3% | ||
| Debt/Equity | 0 |
CHRO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CHRO. The Buy consensus is the average rating of analysts ratings from 7 analysts.